Capecitabine versus classical cyclophosphamide, methotrexate, and fluorouracil as first-line chemotherapy for advanced breast cancer

[1]  B. Hennessy,et al.  Dose-adjusting capecitabine minimizes adverse effects while maintaining efficacy: a retrospective review of capecitabine for metastatic breast cancer. , 2011, Clinical breast cancer.

[2]  A. Schneeweiss,et al.  First-line therapy with moderate dose capecitabine in metastatic breast cancer is safe and active: results of the MONICA trial. , 2010, European journal of cancer.

[3]  J. Sakamoto,et al.  Study of Low-Dose Capecitabine Monotherapy for Metastatic Breast Cancer , 2010, Chemotherapy.

[4]  Xian Zhou,et al.  RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  J. Lokich.  Capecitabine: Fixed Daily Dose and Continuous (Noncyclic) Dosing Schedule , 2004, Cancer investigation.

[6]  David Miles,et al.  Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  E. Winer,et al.  International Guidelines for Management of Metastatic Breast Cancer: Combination vs Sequential Single-Agent Chemotherapy , 2009, Journal of the National Cancer Institute.

[8]  V. Catalano,et al.  Safety profile and activity of lower capecitabine dose in patients with metastatic breast cancer. , 2007, Clinical breast cancer.

[9]  Val Gebski,et al.  Capecitabine versus classical cyclophosphamide, methotrexate, and fluorouracil as first-line chemotherapy for advanced breast cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  M. Naughton.  Evolution of capecitabine dosing in breast cancer. , 2010, Clinical breast cancer.

[11]  H. Burger,et al.  Randomized, open-label, phase II trial of oral capecitabine (Xeloda) vs. a reference arm of intravenous CMF (cyclophosphamide, methotrexate and 5-fluorouracil) as first-line therapy for advanced/metastatic breast cancer. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

[12]  G. Hortobagyi,et al.  Lower dose capecitabine has a more favorable therapeutic index in metastatic breast cancer: retrospective analysis of patients treated at M. D. Anderson Cancer Center and a review of capecitabine toxicity in the literature. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

[13]  A. Buzdar,et al.  Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.